Ameriprise
RXRX icon

Ameriprise’s Recursion Pharmaceuticals RXRX Stock Holding History

Ameriprise’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-37,139
Closed -$114K – 4234
2026
Q1 		$114K Sell
37,139
-5,745
-13% -$22.2K ﹤0.01% 3948
2025
Q4 		$175K Sell
42,884
-2,987
-7% -$14.8K ﹤0.01% 3949
2025
Q3 		$224K Sell
45,871
-4,143
-8% -$21.8K ﹤0.01% 3880
2025
Q2 		$253K Sell
50,014
-43,925
-47% -$216K ﹤0.01% 3756
2025
Q1 		$497K Buy
93,939
+2,269
+2% +$16.5K ﹤0.01% 3486
2024
Q4 		$620K Buy
91,670
+29,034
+46% +$195K ﹤0.01% 3441
2024
Q3 		$413K Sell
62,636
-6,497
-9% -$46.6K ﹤0.01% 3552
2024
Q2 		$518K Sell
69,133
-11,481
-14% -$100K ﹤0.01% 3403
2024
Q1 		$804K Buy
80,614
+40,103
+99% +$447K ﹤0.01% 3259
2023
Q4 		$399K Buy
+40,511
New +$289K ﹤0.01% 3529

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Ameriprise's RXRX Position: Q2 2026 in Review

Ameriprise sold out of Recursion Pharmaceuticals (RXRX) in Q2 2026, closing a stake of 37,139 shares — an estimated $114K sold.

Ameriprise first reported a position in RXRX in Q4 2023 and held it in 10 quarters. The position peaked at $804K in Q1 2024. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Ameriprise reported no remaining Recursion Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Ameriprise sold 37,139 Recursion Pharmaceuticals shares in Q2 2026, an estimated $114K.
  • Ameriprise first reported a position in Recursion Pharmaceuticals in Q4 2023 and held it in 10 quarters.
  • Ameriprise's Recursion Pharmaceuticals position peaked at $804K in Q1 2024.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.